What is Monte Rosa Therapeutics, Inc. (GLUE)?

Monte Rosa Therapeutics, Inc. (GLUE) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of GLUE?

The current price of GLUE is $10.87. Prices are updated in real time on Stocks360.

What is GLUE's price-to-earnings (PE) ratio?

GLUE's trailing twelve-month PE ratio is -4.99, based on current price and earnings per share data available on Stocks360.

What is GLUE's market capitalization?

GLUE's market capitalization is $927,356,658.00, placing it in the small-cap tier.

Monte Rosa Therapeutics, Inc. (GLUE)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$10.87

Market Cap

$927.36M

PE (TTM)

-4.99

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.37

Day Range

$10.73 – $11.18

52-wk Range

$9.68 – $25.77

Avg Volume

N/A

Volume

1.31M

Monte Rosa Therapeutics, Inc. (GLUE) is a publicly traded company in the Healthcare sector. Latest price: $10.87. Market cap $927.36M. Trailing PE -4.99. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $13.01 2026-10-29 · $10.87 (-16.45%)

Earnings

Most Recent

Aug 6, 2026

EPS $-0.43 vs est. $-0.38

Missed by $0.05

Next Earnings

Nov 5, 2026

EPS estimate $-0.24

Proprietary Signals

Signal snapshot temporarily unavailable.

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-4.99×
P/S (TTM)	32.28×
P/B	1.90×
PEG	0.61×
P/FCF (TTM)	-28.91×
EV / EBITDA	-5.62×
EV / Sales	30.47×
Earnings Yield	-17.39%
Free Cash Flow Yield	-3.46%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$875.24M
Revenue (TTM)	$28.73M
Net Income (TTM)	-$161.28M
Free Cash Flow (TTM)	-$32.08M
Net Debt	-$52.12M
Working Capital	$569.52M
Gross Margin	92.94%
Operating Margin	-633.04%
Net Margin	-560.85%
Return on Equity	-43.31%
Return on Invested Capital	-28.19%